Moderna: The Regulatory Speed Paradox
The Software of Life, The Speed of Bureaucracy
When the genetic sequence for SARS-CoV-2 was published in January 2020, Moderna designed their vaccine candidate in approximately two days. The mRNA sequence was synthesized, formulated, and ready for manufacturing within weeks. Then the company waited eleven months for clinical trials, regulatory review, and emergency use authorization. This temporal asymmetry, design measured in days, validation measured in years, defines the central economic paradox of Moderna’s business model. The company has built a platform that treats biology as programmable matter, capable of generating drug candidates with the velocity of software development. Yet the business cannot capture value at the speed of code because the human body remains the ultimate integration environment, and the Food and Drug Administration does not accept agile sprints.
Moderna’s economic engine depends on resolving this tension. The firm operates what is essentially a biotech platform business, where messenger RNA serves as an information molecule that can be rewritten, compiled, and executed by cellular machinery to produce therapeutic proteins. Unlike traditional pharmaceutical development, which requires bespoke chemical synthesis for each new compound, Moderna’s infrastructure is reusable. The same lipid nanoparticle delivery systems, the same manufacturing lines, the same synthesis protocols that produced the COVID-19 vaccine can be redirected to produce an oncology vaccine or a cardiovascular therapeutic with minimal retooling. This reusability creates marginal cost economics that traditional pharma cannot replicate. The second mRNA drug costs materially less to produce than the first because the platform, its robotic factories, its quality control systems, its supply chains, has already been amortized.
Value capture operates through two distinct channels. First, partnership structures with established pharmaceutical companies like AstraZeneca and Alexion, which generated $300 million in combined upfront payments. These deals provide non-dilutive capital to fund platform development while de-risking early-stage research. Second, and more lucratively, wholly-owned drug development where Moderna retains 100 percent of revenue. The COVID-19 vaccine represented the first major proof of the owned-drug model, delivering billions in revenue and validating the manufacturing scale that partnerships alone could not finance. The strategic calculus is clear: partnerships provide oxygen during the capital-intensive phase of platform construction, but owned drugs provide the margin expansion and market capitalization that justify the platform’s existence.
The critical constraint is capital. Building the infrastructure to manufacture mRNA at pharmaceutical grade requires hundreds of millions in sunk costs before a single vial generates revenue. Jason Kelly, who constructed a 200,000-square-foot automated factory for Ginkgo Bioworks at a cost of $400 million, illustrates the capital intensity of modern biomanufacturing. Moderna faced similar economics. The company raised between $400 and $500 million within a year of its AstraZeneca partnership, capital that was immediately consumed by manufacturing buildout and clinical pipeline expansion. This creates a precarious cash flow dynamic. The platform requires massive upfront fixed costs to achieve the marginal cost advantages that make the economics work. If the capital markets close, or if clinical failures delay revenue, the infrastructure becomes a liability rather than a moat.
The Accumulation of Non-Transferable Data
Most analyses of Moderna focus on the mRNA technology itself: he lipid nanoparticles, the modified nucleosides, the sequence optimization. These are replicable. Competitors like BioNTech and CureVac operate with similar biochemical toolkits. The underappreciated structural advantage lies not in the chemistry but in the dataset. Every mRNA sequence Moderna tests, every dosing regimen it validates, every manufacturing run it completes generates proprietary information about how specific genetic codes behave in human cells. This data accumulates non-linearly. A competitor entering the market today cannot purchase five years of Moderna’s empirical learning about which sequences trigger immune responses, which dosages achieve therapeutic thresholds, or which delivery methods avoid hepatic toxicity. They must generate it themselves, experiment by experiment, clinical trial by clinical trial.
This creates an algorithmic advantage that compounds over time. Moderna’s platform is increasingly guided by machine learning models trained on its historical outcomes. The more drugs the company develops, the better it becomes at predicting which mRNA sequences will fold correctly, which will translate efficiently, and which will avoid off-target effects. A startup with equivalent chemical technology but without the historical dataset must run the same experiments Moderna has already completed, spending years and capital to reach the same starting line. The data moat is non-transferable because biological data is context-dependent. You cannot simply download Moderna’s clinical results and apply them; the learning is embedded in the specific protocols, the proprietary modifications, and the tacit knowledge of the scientific team.
This advantage is durable precisely because it is expensive to replicate. A well-funded competitor could build a $400 million factory. They cannot buy five years of failed experiments and subtle optimizations. The dataset represents irreplaceable capital, accumulated through the specific path dependencies of Moderna’s research history.
The Partnership Dilemma
The defining structural constraint shaping Moderna’s strategic decisions is the tension between platform licensing and owned drug development. Partnerships with large pharma provide immediate cash, those $300 million upfront payments, without the dilution of equity financing. They validate the platform to investors and provide access to complementary capabilities in commercialization and late-stage clinical development. But they surrender upside. When Moderna partnered with AstraZeneca for cardiovascular applications, it traded a portion of future revenue for immediate capital and risk-sharing.
Conversely, wholly-owned drugs like the COVID-19 vaccine capture full economics but require the company to bear all capital costs and execution risk. Moderna must decide how to allocate its finite manufacturing capacity and scientific talent between partner programs that fund operations and internal programs that create value. Over-licensing leaves money on the table; under-licensing starves the company of capital before owned drugs reach profitability. This is not a static decision but a continuous rebalancing act that changes as the company matures. In the early years, partnerships were essential to survival. As the COVID vaccine generated cash flow, Moderna could afford to bring more programs in-house, increasing the percentage of revenue it retains but increasing the volatility of its earnings.
The economic variable here is management’s capital allocation discipline. The leadership must resist the temptation to license broadly when cash is tight, preserving optionality for high-value indications. They must also resist the temptation to own everything when capital is flush, avoiding the overextension that destroys execution quality. The decision to retain platform rights outside of specific partnership scopes, maintaining the ability to pivot the same infrastructure to new indications, represents a specific strategic choice to preserve long-term optionality at the cost of short-term partnership revenue.
The Velocity Problem
Moderna’s platform can generate drug candidates in weeks. The FDA approval process takes years. This creates a structural disconnect between the company’s operational capabilities and its value realization timeline. If Moderna cannot convert its design speed into faster clinical outcomes, the platform’s core value proposition collapses. It becomes merely another biotech company with better manufacturing: cost advantage rather than a time advantage.
The clinical trial bottleneck is not merely a regulatory delay; it is an existential risk to the business model. The platform’s economic justification rests on the assumption that rapid design iteration allows for more shots on goal, increasing the probability of clinical success. But if the limiting factor is always the three-year Phase 3 trial, then the ability to design ten candidates in the time it takes a competitor to design one provides limited advantage. The capital is still consumed at the pace of clinical development. The burn rate is determined by trial costs, not design costs.
This tension shapes every strategic priority. Moderna must select indications where the clinical trial pathway is shortest or where biomarkers allow for accelerated approval. It must invest in manufacturing scale that can flex rapidly to support unexpected clinical needs. The company’s culture must tolerate the psychological asymmetry of moving at startup speed while trapped in a regulatory framework designed for an earlier era of drug development. If the organization loses discipline and begins to believe its own headlines about “software-like” speed, it risks overcommitting to programs before clinical validation, burning capital on candidates that fail in the only arena that matters: the human body.
The Second Drug Test
Moderna’s valuation and strategic position rest on a fragile assumption: that the COVID-19 vaccine was not a one-off success but proof of a repeatable platform. The company must demonstrate that mRNA works across multiple therapeutic modalities, infectious disease, oncology, cardiovascular, rare diseases, or the platform narrative dissolves. A major clinical failure in a second significant indication would suggest that mRNA efficacy is limited to specific viral antigens, or that Moderna’s manufacturing and dosing approach has fundamental flaws that did not appear in the COVID emergency use context.
This fragility is acute because the COVID vaccine benefited from unique circumstances: massive government funding, accelerated regulatory pathways, a global pandemic that allowed for rapid efficacy readouts due to high infection rates, and pricing power derived from emergency demand. The next drug, whether an RSV vaccine, a cancer therapeutic, or a personalized neoantigen vaccine, will face normal commercial conditions. It will compete in crowded markets with established standards of care. It will face pricing pressure from insurers and governments no longer operating under emergency protocols.
Jason Kelly’s observation that Moderna becomes “the obvious bet to be the Genentech” only if they land a second major drug captures the binary nature of this transition. Genentech’s valuation and strategic position rested not on a single successful molecule but on a platform that repeatedly produced blockbusters. Until Moderna proves this repeatability, it remains a company that had one extraordinary success. The capital markets will treat it accordingly, assigning a multiple that reflects single-product risk rather than platform value. The $400 million factories and the algorithmic data advantages only generate returns if they can be applied to multiple approved drugs. A platform that produces one drug is merely an expensive R&D project.
When the Code Commoditizes
The underlying mRNA synthesis and delivery technology is becoming commoditized. BioNTech, CureVac, and a host of startups operate with equivalent biochemical foundations. The patents on basic mRNA modification will expire. If Moderna’s moat rests solely on its chemical IP, it will erode rapidly. The company’s long-term defensibility depends instead on the integration of manufacturing scale, regulatory know-how, and the proprietary data accumulated through its specific development history.
This creates a race against time. Moderna must convert its current technological lead into structural advantages that survive commoditization. The data moat must widen faster than competitors can run their own experiments. The manufacturing infrastructure must achieve such scale and efficiency that new entrants cannot justify the capital expenditure to compete on cost. The clinical trial expertise must become so specialized to mRNA modalities that regulatory pathways are faster for Moderna than for newcomers.
If the company fails to build these structural barriers, it faces a future where mRNA becomes a commodity input, like monoclonal antibodies or small molecules, and Moderna becomes merely one manufacturer among many. The $300 million partnership upfronts will shrink as pharma companies realize they can access equivalent technology elsewhere. The pricing power on owned drugs will erode as biosimilars emerge. The platform economics that justify the massive capital investment will collapse into the economics of a contract manufacturing organization, rofitable but uninspiring, valued on EBITDA multiples rather than platform premiums.
The Fragile Assumption of Biological Generality
At the foundation of Moderna’s business model lies an unproven hypothesis: that mRNA can be successfully delivered into human cells across diverse tissue types and disease indications without triggering unacceptable immune responses or off-target effects. The COVID vaccine worked because it required only transient protein expression in muscle cells to trigger an immune response. Cancer vaccines may require sustained expression in the tumor microenvironment. Cardiovascular applications may require targeting specific cell types in the heart. Each indication presents unique delivery challenges, immunogenicity risks, and dosing complexities.
If mRNA proves effective only for infectious diseases, where transient, high-level antigen expression is therapeutic, the addressable market shrinks dramatically. If the technology cannot solve the delivery problem for intracellular targets in solid tumors, the oncology pipeline fails. Moderna has placed bets across dozens of indications, spreading capital and talent thin to maintain optionality. But the platform thesis requires that a significant percentage of these bets succeed. The marginal cost economics only work at volume. A platform that works for three diseases is a manufacturing advantage. A platform that works for thirty is a transformation of the pharmaceutical industry.
The leadership’s decision to pursue breadth over depth, developing vaccines for RSV, CMV, HIV, Zika, cancer, heart disease, and rare diseases simultaneously, reflects a strategic choice to test the limits of biological generality. It is a capital-intensive experiment. Each failed indication not only wastes the direct R&D spend but narrows the platform’s perceived applicability, reducing the premium investors assign to the manufacturing infrastructure.
Culture as Economic Variable
Moderna’s ability to navigate these tensions depends on specific organizational capabilities that function as economic variables. The company must maintain a culture that tolerates extreme capital intensity without becoming reckless, that pursues scientific breadth without sacrificing execution depth, and that manages partnerships without becoming dependent on them. Stéphane Bancel’s leadership has emphasized manufacturing discipline and capital efficiency in ways that directly affect returns. The decision to build internal manufacturing capacity rather than outsource, a choice that consumed hundreds of millions in capital, was a bet that vertical integration would generate cost advantages that outsourcing could not match.
This manufacturing culture is not merely operational detail; it is the difference between a platform business and a research boutique. If Moderna had outsourced manufacturing, it would have captured less margin on the COVID vaccine and would lack the capacity to rapidly pivot to new indications. The willingness to invest $400 million in robotic factories before proving the platform’s generality represents a specific risk appetite that most biotech companies lack. This capital intensity is a barrier to entry for competitors but also a burning fuse for Moderna if the clinical pipeline falters.
The organization must also maintain the scientific culture necessary to exploit its data advantages. The platform generates terabytes of experimental data, but this data only creates value if the company can convert it into better drug designs. This requires computational biology capabilities, machine learning infrastructure, and organizational processes that allow data scientists and bench scientists to collaborate effectively. If Moderna becomes a traditional pharmaceutical company with fancy manufacturing, it will lose the algorithmic advantages that justify its valuation premium.
The Economic Horizon
Moderna stands at an inflection point where its strategic choices will determine whether it becomes a durable platform company or a cautionary tale about one-hit wonders. The company has proven that mRNA can be manufactured at scale and can generate massive revenue in emergency contexts. It has not yet proven that the platform can generate a diversified portfolio of approved drugs with sustainable competitive advantages.
The economics of the business depend on a virtuous cycle: partnership revenue and initial drug profits fund manufacturing expansion, which lowers costs and enables more owned-drug development, which generates data that improves the platform’s success rate, which justifies further capital investment. If any link in this chain breaks, f clinical trials fail at higher rates than expected, if manufacturing scale does not yield cost advantages, if data accumulation does not improve design success: he cycle reverses. Capital becomes expensive, partnerships become necessary rather than optional, and the platform loses its premium valuation.
The next five years will test whether Moderna can convert its biochemical technology into structural economic advantages. The factories are built. The data is accumulating. The partnerships are in place. Now the company must prove that it can run the clinical gauntlet faster and more successfully than competitors with deeper pockets and more established pipelines. The software of life is written. Whether it compiles into a durable business model remains the open question.
The Manufacturing Margin and the Physics of Scale
The $400 million factory is not merely a facility; it is a statement about the physics of pharmaceutical production. Traditional biologics manufacturing, monoclonal antibodies, recombinant proteins, requires living cell cultures, stainless steel bioreactors, and purification processes that are essentially artisanal. Each batch depends on the health of Chinese hamster ovary cells, sensitive to temperature fluctuations, viral contamination, and the biological variability of living systems. Moderna’s mRNA production, by contrast, is enzymatic synthesis. It is chemistry, not agriculture. The DNA template is mixed with nucleotides and enzymes in a reaction vessel; the mRNA is transcribed, purified, and encapsulated in lipid nanoparticles. The process is closer to semiconductor fabrication than to brewing.
This distinction creates a different margin structure at scale. Biological manufacturing faces fundamental constraints: cell density limits, batch failure rates, and the inability to run continuous processes. mRNA synthesis can be automated, monitored in real-time, and adjusted algorithmically. The Ginkgo Bioworks facility that Jason Kelly constructed, the 200,000-square-foot plant with extensive robotics processing 50 million letters of DNA monthly, illustrates the throughput acceleration possible when biology becomes an information technology. Moderna’s Norwood, Massachusetts manufacturing site operates on similar principles. Where traditional biotech might measure output in grams of protein, Moderna measures output in doses, with each dose containing micrograms of mRNA. The mass efficiency is extraordinary, but only if the fixed costs of the facility are amortized across billions of doses.
The capital efficiency question thus resolves to a utilization problem. In 2021 and 2022, Moderna operated its factories at capacities that justified the capital expenditure. The COVID vaccine demand absorbed fixed costs, drove unit economics toward theoretical minima, and generated the cash flow necessary to fund expansion. But as pandemic demand normalizes, Moderna faces the idle capacity problem. A $400 million factory with 50% utilization is a drag on margins; at 20% utilization, it becomes a crisis. The company must fill this capacity with clinical trial materials, partnered products, and owned-drug commercial supply, or the platform economics invert. The very infrastructure that creates the marginal cost advantage becomes an albatross if the pipeline does not produce approved drugs rapidly enough to feed the machines.
This creates a specific operational tension: the manufacturing schedule drives the clinical timeline rather than the reverse. Traditional pharmaceutical companies manufacture clinical trial materials in small batches, scaling only after approval. Moderna’s fixed cost structure demands continuous production to maintain operational efficiency. The company must therefore advance drugs to clinical stages faster than might be optimal scientifically, simply to keep the factories running. This pressure to fill capacity can lead to premature Phase 1 initiations, spreading resources across marginal candidates that would not survive rigorous prioritization in a capital-light model. The manufacturing moat becomes a prison of sunk costs, forcing the company to feed the infrastructure with clinical programs that may not merit the investment.
The Immunogenicity Trap
The bear case on biological generality rests on a specific technical challenge that the COVID vaccine did not fully resolve: immunogenicity. The human immune system evolved to detect foreign RNA as a pathogen signal. When synthetic mRNA enters cells, it triggers pattern recognition receptors, specifically Toll-like receptors and RIG-I-like receptors, that initiate inflammatory cascades. Moderna and BioNTech have developed modified nucleosides (specifically pseudouridine and N1-methylpseudouridine) that partially evade these sensors, allowing the mRNA to translate proteins without immediate immune clearance. But “partially” is the operative word.
In the context of infectious disease vaccines, transient inflammation is acceptable, even desirable, as it provides adjuvant effect. In oncology, where the goal is to express tumor antigens over extended periods to train T-cell responses, chronic inflammation is problematic. It can lead to systemic cytokine release, autoimmunity, or simply rapid clearance of the mRNA before therapeutic protein levels are achieved. The dose escalation required to overcome clearance may trigger unacceptable toxicity. If Moderna’s cancer vaccines fail in Phase 2 due to dose-limiting immunogenicity, the platform’s addressable market contracts to acute, single-dose applications, infectious diseases, where pricing pressure is highest and competitive differentiation is hardest to maintain.
Cardiovascular applications present different delivery challenges. The liver naturally absorbs lipid nanoparticles, making hepatic targets (certain metabolic diseases, some infectious diseases) technically straightforward. But myocardial tissue, the endothelium, or specific neuronal populations require targeting ligands and formulation modifications that have not been clinically validated. If the lipid nanoparticles cannot be engineered to deliver mRNA to cardiac muscle cells without accumulation in the liver (which causes off-target protein expression and potential toxicity), the cardiovascular pipeline fails. Moderna’s partnership with AstraZeneca for cardiovascular and metabolic diseases thus represents a specific de-risking strategy: they have outsourced the clinical validation of tissue-specific delivery to a partner with deeper expertise and greater risk tolerance for late-stage failure.
The regulatory fragility extends beyond efficacy to safety surveillance. The COVID vaccines were approved under emergency use authorization with follow-up periods measured in months. As mRNA drugs move into chronic indications requiring repeated dosing over years, the FDA will demand long-term safety data on immunogenicity, off-target effects, and potential integration into host genomes (theoretical but unproven). If post-market surveillance identifies rare but serious adverse events, myocarditis was already identified as a signal in young males with COVID mRNA vaccines, the agency could impose Risk Evaluation and Mitigation Strategies (REMS), restricted indications, or enhanced monitoring that increase the cost of commercialization and limit addressable markets. A platform dependent on broad applicability cannot survive narrow labeling.
The Partnership Architecture and the Reserve Capacity Calculation
The tension between platform licensing and owned drug development manifests in specific contractual structures that evolved as Moderna matured. The early AstraZeneca deal (2013) granted the pharma giant rights to specific cardiovascular targets in exchange for $240 million upfront and milestone payments, but critically, Moderna retained platform rights outside the defined targets. This was not a template deal; it was a carefully constructed compromise that allowed Moderna to fund infrastructure without surrendering the COVID vaccine rights a decade later. The Alexion deal (2014) for rare diseases followed similar logic but with different economic terms reflecting the smaller market sizes but higher pricing power in rare indications.
These partnerships created a reserve capacity problem. Moderna had to allocate manufacturing slots and scientific talent to AstraZeneca’s programs while reserving capacity for internal pipeline acceleration. If the AstraZeneca drug succeeded, Moderna would receive royalties but would be contractually obligated to supply product from facilities that might be needed for higher-margin owned drugs. If the AstraZeneca drug failed, the partnership revenue would cease, but the capacity reserved for that partner would sit idle, creating a drag on returns. The optimal reserve capacity, how much manufacturing and scientific bandwidth to keep uncommitted for internal use versus dedicated to partners, changes as the company’s cash position and clinical maturity evolve.
Moderna’s response to this tension has been increasingly conservative. As COVID revenue materialized, the company allowed early partnerships to expire or convert to less restrictive terms, bringing programs back in-house. This reversal of the early strategy, moving from partnered to owned, requires specific organizational capabilities. Moderna had to build commercial infrastructure (sales forces, marketing, market access teams) that the partnerships had allowed them to defer. The economic trade-off shifted: the cost of building a commercial organization (hundreds of millions annually) had to be weighed against the margin loss to partners. For a drug with $1 billion peak sales potential, owning 100% rather than receiving 15% royalties justifies significant commercial infrastructure investment. For drugs with smaller markets, the partnership economics remain superior.
The Data Accumulation Race with BioNTech
The assumption that Moderna’s data moat widens faster than competitors can replicate it faces a specific challenge in BioNTech. The German company developed the Pfizer-partnered COVID vaccine contemporaneously, operates similar mRNA technology, and has generated comparable datasets regarding COVID spike protein expression, lipid nanoparticle distribution, and immunogenicity profiles. If Moderna’s advantage rests solely on cumulative experimental data, BioNTech’s parallel development suggests the moat may be narrower than assumed.
However, the data moat’s durability depends on the specificity of learning. Moderna’s dataset includes not just COVID data but years of failed oncology trials, abandoned cardiovascular candidates, and iterative optimizations of manufacturing parameters that BioNTech may not have pursued. The value lies in the negative results: he sequences that did not fold correctly, the formulations that caused unacceptable liver enzymes, the dosing schedules that failed to achieve therapeutic thresholds. BioNTech, having pursued a different pipeline strategy (heavier emphasis on oncology earlier, different partnership structures), has generated different data. The platforms are converging in capability but diverging in specific empirical knowledge.
This creates a race condition. If Moderna can convert its data into a second approved drug before BioNTech does, the cumulative learning from two distinct therapeutic areas (infectious disease and, say, oncology) creates compounding advantages for a third and fourth indication. If BioNTech reaches the second approval first, the empirical gap narrows. The data moat is not static; it requires continuous successful translation of data into approved drugs to maintain its value. A platform that accumulates data but fails to generate approvals becomes a graveyard of interesting but non-commercial science.
The Capital Re-investment Problem
Moderna’s COVID windfall, tens of billions in revenue over two years, created a specific capital allocation challenge that now threatens the platform’s economics. The company must deploy this capital to build the pipeline and manufacturing capacity that will sustain revenue as COVID demand declines, but it must do so without the discipline-imposing constraint of scarce capital. Flush with cash, Moderna has expanded its pipeline to dozens of candidates simultaneously, funding early-stage programs in Zika, HIV, autoimmune diseases, and personalized cancer vaccines that would not have survived prioritization in a capital-constrained environment.
This breadth risks the depth of execution that the platform requires. Each clinical trial failure wastes not just the direct R&D spend but the opportunity cost of management attention and manufacturing capacity. In a constrained environment, Moderna would have selected three or four high-conviction programs and executed them flawlessly. With abundant capital, they have pursued breadth, increasing the statistical probability that at least one program succeeds but potentially reducing the quality of execution across all programs. The organizational bandwidth of a 3,000-person company is finite; spreading it across forty clinical programs rather than ten may reduce the success rate per program below the threshold where platform economics work.
The bear case on capital allocation suggests that Moderna will burn through its COVID reserves funding marginal indications, achieve only incremental approvals, and find itself in 2027 with an empty pipeline, idle factories, and no second blockbuster. At that point, with the stock repriced to reflect single-product risk and the cash depleted, the company would be forced into dilutive financings or fire-sale partnerships that surrender the economics they fought to retain. The platform’s durability depends not on the technology alone but on the discipline to say no to scientifically interesting but commercially marginal applications: discipline that abundant capital erodes.
The Regulatory Paradigm Shift
A final fragility lies in the implicit assumption that the FDA’s regulatory framework for mRNA will remain stable. The agency’s experience with COVID vaccines created a template for accelerated review of infectious disease mRNA products, but this template may not transfer to chronic diseases or gene editing applications. If the FDA determines that lipid nanoparticle accumulation in organs requires longer-term safety studies, or that the immunogenicity profile of repeated mRNA dosing necessitates novel efficacy thresholds, Moderna’s clinical timelines could extend by years.
More dangerously, if political or social resistance to mRNA technology hardens, driven by vaccine hesitancy movements or adverse event reports, the regulatory environment could shift from accommodative to restrictive. The FDA could demand real-world evidence studies post-approval, impose restrictive labeling, or simply slow review timelines to allow for extended safety monitoring. Moderna’s valuation depends on the assumption that mRNA drugs will reach market faster than traditional biologics. If regulatory parity is achieved, if mRNA faces the same development timelines as antibodies or small molecules, the platform’s time advantage disappears, and with it the economic justification for the manufacturing infrastructure and the premium valuation.